Abivax Joins Nasdaq Biotechnology Index

Abivax SA, a clinical-stage biotechnology company based in Paris, has announced its inclusion in the Nasdaq Biotechnology Index (NBI) effective December 22, 2025. Known for its work on therapeutics for chronic inflammatory diseases, Abivax showcased significant progress with its lead drug candidate, obefazimod. This substance recently advanced through successful Phase 3 ABTECT Induction trials addressing ulcerative colitis.

The inclusion in the NBI highlights Abivax's rising visibility within the global biotechnology sector. The NBI tracks the performance of biotech and pharmaceutical securities on Nasdaq and includes companies meeting strict criteria, such as market capitalization and trading volume. Evaluation occurs yearly, employing a modified capitalization-weighted methodology.